Skip to the page

Data / Drug companies / Amneal Pharmaceuticals NY LLC

Amneal Pharmaceuticals NY LLC: 110 products in the FDA NDC directory, labeler code 60219

Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).

Amneal Pharmaceuticals NY LLC (labeler code 60219) lists 110 products in the FDA National Drug Code Directory, covering 48 finished drugs by generic name. By type: 109 prescription drugs, 1 over the counter drugs. Its main marketing category is generic drugs (ANDA). The newest product started marketing on January 15, 2026.

The request: Watch Amneal Pharmaceuticals NY LLC (FDA labeler code 60219): each new product listing and each discontinued product. $10 of work on sign-up, no card.

SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.

Labeler code
60219
Products in commercial distribution
110
Packages
158
Finished drugs by generic name
48
Prescription products
109
Over the counter products
1
Controlled substance products
Schedule IV 2, Schedule V 8
Flagged as original packager
99 of 99 products that carry the flag
Started marketing in the last 12 months
8
Earliest marketing start
May 1, 2007
openFDA record search
api.fda.gov

Products by marketing category

Share of the company's products in commercial distribution.

Marketing categoryProductsShare
Generic drugs (ANDA)110100%

Products by type

TypeProductsShare
Prescription drugs10999.1%
Over the counter drugs10.9%

Drugs it lists

Finished drugs by generic name, with how many companies list each.

Dosage forms

Dosage formProductsShare
Capsule2926.4%
Tablet2220%
Tablet, film coated2018.2%
Suspension/ drops98.2%
Solution/ drops87.3%
Tablet, extended release43.6%
Injection, suspension32.7%
Powder, for suspension32.7%
Tablet, for suspension32.7%
For solution21.8%
Suspension21.8%
Kit10.9%

Pharmacologic classes

FDA established pharmacologic classes of its products.

Newest products

By marketing start date.

ProductProduct NDCDosage formMarketing categoryMarketing start
Eltrombopag Olamine60219-1417Tablet, film coatedGeneric drugs (ANDA)January 15, 2026
Eltrombopag Olamine60219-1416Tablet, film coatedGeneric drugs (ANDA)January 15, 2026
Eltrombopag Olamine60219-1415Tablet, film coatedGeneric drugs (ANDA)January 15, 2026
Eltrombopag Olamine60219-1414Tablet, film coatedGeneric drugs (ANDA)January 15, 2026
Deflazacort60219-2285TabletGeneric drugs (ANDA)December 12, 2025
Deflazacort60219-2284TabletGeneric drugs (ANDA)December 12, 2025
Deflazacort60219-2283TabletGeneric drugs (ANDA)December 12, 2025
Deflazacort60219-2282TabletGeneric drugs (ANDA)December 12, 2025
Neomycin and polymyxin b sulfates and hydrocortisone60219-2083Solution/ dropsGeneric drugs (ANDA)October 29, 2025
Neomycin and polymyxin b sulfates and hydrocortisone60219-2084Suspension/ dropsGeneric drugs (ANDA)September 30, 2025
Bimatoprost60219-2149Solution/ dropsGeneric drugs (ANDA)September 22, 2025
Pilocarpine Hydrochloride Ophthalmic60219-2649Solution/ dropsGeneric drugs (ANDA)September 1, 2025
Prednisolone acetate60219-2552Suspension/ dropsGeneric drugs (ANDA)June 13, 2025
Prednisolone acetate60219-2551Suspension/ dropsGeneric drugs (ANDA)June 13, 2025
Prednisolone acetate60219-2550Suspension/ dropsGeneric drugs (ANDA)June 13, 2025
Medroxyprogesterone Acetate60219-1467Injection, suspensionGeneric drugs (ANDA)June 10, 2025
Loteprednol etabonate60219-1362Suspension/ dropsGeneric drugs (ANDA)May 22, 2025
Pilocarpine Hydrochloride Ophthalmic60219-2366Solution/ dropsGeneric drugs (ANDA)May 1, 2025
Lenalidomide60219-1719CapsuleGeneric drugs (ANDA)February 12, 2025
Lenalidomide60219-1718CapsuleGeneric drugs (ANDA)February 12, 2025
Lenalidomide60219-1717CapsuleGeneric drugs (ANDA)February 12, 2025
Lenalidomide60219-1716CapsuleGeneric drugs (ANDA)February 12, 2025
Lenalidomide60219-1715CapsuleGeneric drugs (ANDA)February 12, 2025
Lenalidomide60219-1714CapsuleGeneric drugs (ANDA)February 12, 2025
Everolimus60219-2281Tablet, for suspensionGeneric drugs (ANDA)January 14, 2025

CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.